These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 31685033)

  • 41. Erdheim-Chester disease with an 18F-fluorodeoxyglucose-avid breast mass and BRAF V600E mutation.
    Furuta T; Kiryu S; Yamada H; Hosoi M; Kurokawa M; Morikawa T; Shibahara J; Ohtomo K
    Jpn J Radiol; 2014 May; 32(5):282-7. PubMed ID: 24531980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Central nervous system involvement in Erdheim-Chester disease: An observational cohort study.
    Cohen Aubart F; Idbaih A; Galanaud D; Law-Ye B; Emile JF; Charlotte F; Donadieu J; Maksud P; Seilhean D; Amoura Z; Hoang-Xuan K; Haroche J
    Neurology; 2020 Nov; 95(20):e2746-e2754. PubMed ID: 32887776
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
    Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An effective treatment in Erdheim Chester disease: vemurafenib: a case report.
    Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
    J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
    Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erdheim-Chester disease involving the breast--a rare but important differential diagnosis.
    Guo S; Yan Q; Rohr J; Wang Y; Fan L; Wang Z
    Hum Pathol; 2015 Jan; 46(1):159-64. PubMed ID: 25454479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.
    Haroun F; Millado K; Tabbara I
    Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [An overview of histiocytosis].
    Tojo A
    Rinsho Ketsueki; 2022; 63(5):363-367. PubMed ID: 35662158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
    Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cytologic diagnosis of BRAF
    Chasseur P; Kyriakopoulou M; Vokaer B; Beukinga I; Casado Arroyo R; Cogan E; Couturier B
    Acta Clin Belg; 2017 Oct; 72(5):369-371. PubMed ID: 28222655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
    Janku F; Diamond EL; Goodman AM; Raghavan VK; Barnes TG; Kato S; Abdel-Wahab O; Durham BH; Meric-Bernstam F; Kurzrock R
    Mol Cancer Ther; 2019 Jun; 18(6):1149-1157. PubMed ID: 31015311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.
    Janku F; Vibat CR; Kosco K; Holley VR; Cabrilo G; Meric-Bernstam F; Stepanek VM; Lin PP; Leppin L; Hassaine L; Poole JC; Kurzrock R; Erlander MG
    Oncotarget; 2014 Jun; 5(11):3607-10. PubMed ID: 25003820
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vemurafenib as first-line therapy in
    Fernández-Eulate G; Muñoz-Lopetegi A; Ruiz I; Urtasun M
    BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31748352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Erdheim-Chester disease with bilateral Achilles tendon involvement.
    Nadjiri J; Woertler K; Specht K; Harrasser N; Toepfer A
    Skeletal Radiol; 2016 Oct; 45(10):1437-42. PubMed ID: 27506209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Central nervous system disorders secondary to histiocytoses: neurodegeneration with potential for improvement].
    Morimoto A; Sakamoto K; Kudo K; Shioda Y
    Rinsho Shinkeigaku; 2024 Feb; 64(2):85-92. PubMed ID: 38281751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case of Erdheim-Chester disease with the
    Matsuhisa T; Teranishi M; Tsuyuki Y; Sone M; Sato J
    Nagoya J Med Sci; 2023 Feb; 85(1):150-156. PubMed ID: 36923612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histopathological and Clinical Findings in Cutaneous Manifestation of Erdheim-Chester Disease and Langerhans Cell Histiocytosis Overlap Syndrome Associated With the BRAFV600E Mutation.
    Liersch J; Carlson JA; Schaller J
    Am J Dermatopathol; 2017 Jul; 39(7):493-503. PubMed ID: 27898473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
    Aggarwal A; Taychert M; Hasanin L; Doll D; Basuino MG; Hasanein H
    Oncology (Williston Park); 2023 Jul; 37(7):298-302. PubMed ID: 37499251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
    Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
    Front Immunol; 2022; 13():918613. PubMed ID: 35874752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.